Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

Breast Cancer Research and Treatment
T FrogneAnne E Lykkesfeldt

Abstract

Seven fulvestrant resistant cell lines derived from the estrogen receptor alpha positive MCF-7 human breast cancer cell line were used to investigate the importance of epidermal growth factor receptor (ErbB1-4) signaling. We found an increase in mRNA expression of EGFR and the ErbB3/ErbB4 ligand heregulin2 (hrg2) and a decrease of ErbB4 in all resistant cell lines. Western analyses confirmed the upregulation of EGFR and hrg2 and the downregulation of ErbB4. Elevated activation of EGFR and ErbB3 was seen in all resistant cell lines and the ErbB3 activation occurred by an autocrine mechanism. ErbB4 activation was observed only in the parental MCF-7 cells. The downstream kinases pAkt and pErk were increased in five of seven and in all seven resistant cell lines, respectively. Treatment with the EGFR inhibitor gefitinib preferentially inhibited growth and reduced the S phase fraction in the resistant cell lines concomitant with inhibition of Erk and unaltered Akt activation. In concert, inhibition of Erk with U0126 preferentially reduced growth of resistant cell lines. Treatment with ErbB3 neutralizing antibodies inhibited ErbB3 activation and resulted in a modest but statistically significant growth inhibition of two resistant cel...Continue Reading

References

May 16, 1995·International Journal of Cancer. Journal International Du Cancer·A E LykkesfeldtP Briand
Nov 26, 1998·The New England Journal of Medicine·C K Osborne
Jun 12, 2003·The Journal of Steroid Biochemistry and Molecular Biology·Anette SommerKarsten Parczyk
Jul 8, 2003·The Journal of Pathology·Caroline J WittonJohn M S Bartlett
Oct 9, 2003·Breast Cancer Research and Treatment·Iain R HutchesonRobert I Nicholson
Jan 15, 2004·The Journal of Biological Chemistry·Norihiko NakanoYoshinao Wada
May 14, 2004·The Journal of Pathology·Mariana DunnWilliam J Gullick
Sep 21, 2004·Breast Cancer Research and Treatment·Nicola J JordanRobert I Nicholson
Feb 11, 2005·International Journal of Cancer. Journal International Du Cancer·Edward Htun van der HorstAxel Ullrich
Mar 1, 2005·Cancer Research·Teemu T JunttilaKlaus Elenius
Apr 29, 2005·Current Drug Targets·N NormannoD S Salomon
May 3, 2005·Nature Reviews. Cancer·Nancy E Hynes, Heidi A Lane
Aug 10, 2005·The Journal of Pathology·Tove KirkegaardJohn M S Bartlett
Sep 20, 2005·Breast Cancer Research : BCR·Guojun WuDavid Sidransky
Nov 2, 2005·Breast Cancer Research and Treatment·D J BrittonR I Nicholson
Jul 11, 2006·Nature Reviews. Molecular Cell Biology·Ami Citri, Yosef Yarden
Sep 7, 2006·Endocrine-related Cancer·Anthony Howell
Sep 21, 2006·Expert Reviews in Molecular Medicine·Cynthia A Zahnow
Nov 7, 2006·Trends in Cell Biology·Bryan Linggi, Graham Carpenter
Feb 3, 2007·International Journal of Cancer. Journal International Du Cancer·Bolin LiuAnn D Thor
May 9, 2007·Reviews in Endocrine & Metabolic Disorders·R I NicholsonJ M W Gee
May 29, 2007·Cellular and Molecular Life Sciences : CMLS·M Breuleux
Aug 10, 2007·Breast Cancer Research : BCR·Iain R HutchesonRobert I Nicholson
Oct 20, 2007·Biochemical and Biophysical Research Communications·Kristy J WilsonDavid J Riese

❮ Previous
Next ❯

Citations

Mar 10, 2011·Breast Cancer Research and Treatment·Roopali Roy, Marsha A Moses
Jul 11, 2012·International Journal of Surgical Oncology·Elena LastraioliAnnarosa Arcangeli
Feb 25, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marcia R CampbellMark M Moasser
Oct 4, 2011·The Journal of Clinical Investigation·Michaela J Higgins, José Baselga
Jun 7, 2011·Breast Cancer Research : BCR·Robert L Sutherland
Oct 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Todd W MillerCarlos L Arteaga
Aug 31, 2013·PloS One·Marianne Hauglid FlågengGunnar Mellgren
Dec 22, 2009·Future Oncology·Maija Hollmén, Klaus Elenius
Oct 27, 2012·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Saori FujiwaraHirotaka Iwase
Apr 25, 2012·Breast Cancer Research and Treatment·Christina W YdeAnne E Lykkesfeldt
Jul 17, 2015·International Journal of Cancer. Journal International Du Cancer·Amit AgrawalJulia M W Gee
Aug 3, 2012·The Breast : Official Journal of the European Society of Mastology·Mathilde S LarsenBirgitte B Rasmussen
Nov 28, 2015·Endocrine-related Cancer·Martyn Bullock
Jan 24, 2012·The Journal of Steroid Biochemistry and Molecular Biology·Cynthie Wong, Shiuan Chen
Sep 4, 2010·Seminars in Cell & Developmental Biology·John FoleyDavid J Riese
Aug 16, 2015·Molecular and Cellular Endocrinology·Michelle M BoisenSteffi Oesterreich
Jul 18, 2009·International Journal of Cancer. Journal International Du Cancer·Sandra E GhayadPascale A Cohen
Jun 10, 2014·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Mi Ryoung ChoiSug Hyung Lee
Apr 8, 2015·Breast Cancer Research : BCR·Xiu-Rong RenWei Chen
Apr 22, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Khalil ZamanPatrick Neven
Mar 1, 2011·Hormone Molecular Biology and Clinical Investigation·Julia M W GeeIain R Hutcheson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.